The UK's Proximagen Neuroscience says that it has hit its first milestone under the terms of its deal with Upsher-Smith Laboratories. The milestone, which was triggered when Proximagen reported positive pre-clinical results on the PRX1 program, comes with a $6 million payment. Release
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments